ArticleBMC cancer2023
Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- The prognostic role of maximum tumor dissemination derived by PET/CT in oncological diseases: a systematic review.Frontiers in medicine · 2025Pooled it
- Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma.World journal of urology · 2026Article
- Article
- Metabolic Bulk Volume is an independent prognostic factor and facilitates identifying high risk cases for DLBCL patients treated with the R-CHOP.Frontiers in oncology · 2026Article
- Inter-reader agreement of quantitative FDG PET/CT biomarkers in lymphoma: a multicentre evaluation of MTV, TLG and Dmax.BMC medical imaging · 2025Article
- Fast 4D-PET parametric imaging computation at the whole field of view level: Reliability under simulated conditions of PET KinetiX, a dedicated software solution.European journal of nuclear medicine and molecular imaging · 2025Article
- Prognostic value of early post-treatmentCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
background
methodsData of newly diagnosed DLBCL at the Third Affiliated Hospital of Soochow University were retrospectively collected. Baseline Dmax, clinical data and survival information were recorded. A metabolic parameter, metabolic bulk volume (MBV), was also measured to verify the independent impact of Dmax.
resultsOptimal cut-off values for Dmax and MBV were 45.34 cm and 21.65 cm
conclusionDmax is a new and promising indicator to investigate dissemination of lymphoma lesions associated with the outcome of DLBCL. It significantly contributes to stratification of patients with disparate outcomes.
trial registrationThis research has been retrospectively registered in the Ethics Committee institutional of the Third Affiliated Hospital of Soochow University, and the registration number was approval No. 155 (approved date: 31 May 2022).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.